Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

Congressional lawmakers are trading millions in pharmaceutical stocks as the Trump administration vies to overhaul the ...

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.

Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study, sending its shares up by more than 140% in premarket trading. In the 393-patient trial, ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...